Acute Myeloid Leukemia Stem Cells: Seek and Destroy

Overview

Journal Expert Rev Hematol

Specialty Hematology

Date 2010 Nov 19

PMID 21082958

Citations 32

Authors

Gail J Roboz

Monica Guzman

Affiliations

Soon will be listed here.

Abstract

Most adult patients with acute myeloid leukemia (AML) die from their disease. Relapses are frequent even after aggressive multiagent chemotherapy and allogeneic stem cell transplantation. AML is a biologically heterogeneous disease, characterized by frequent cytogenetic abnormalities and an increasing spectrum of genetic mutations and molecular aberrations. Laboratory data suggest that AML originates from a rare population of cells, termed leukemic stem cells (LSCs) or leukemia-initiating cells, which are capable of self-renewal, proliferation and differentiation. These cells may persist after treatment and are probably responsible for disease relapse. This review will describe bench and translational research in LSCs and discuss how the data should be used to change the direction of developmental therapeutics and clinical trials in AML.

Citing Articles

MALAT1/miR-582-5p/GALNT1/MUC1 axis modulates progression of AML leukemia stem cells by regulating JAK2/STAT3 pathway.

Li S, Gao R, Han X, Wang K, Kang B, Ma X Ann Hematol. 2024; 103(12):5273-5283.

PMID: 39428449 DOI: 10.1007/s00277-024-06043-w.

Doxorubicin-Loaded Polymeric Micelles Conjugated with CKR- and EVQ-FLT3 Peptides for Cytotoxicity in Leukemic Stem Cells.

Chueahongthong F, Tima S, Chiampanichayakul S, Dejkriengkraikul P, Okonogi S, Sasarom M Pharmaceutics. 2022; 14(10).

PMID: 36297550 PMC: 9610626. DOI: 10.3390/pharmaceutics14102115.

Leukemic Stem Cell: A Mini-Review on Clinical Perspectives.

Barreto I, DE Pinho Pessoa F, Machado C, da Costa Pantoja L, Ribeiro R, Lopes G Front Oncol. 2022; 12:931050.

PMID: 35814466 PMC: 9270022. DOI: 10.3389/fonc.2022.931050.

Krüppel-like Factor 4 Supports the Expansion of Leukemia Stem Cells in MLL-AF9-driven Acute Myeloid Leukemia.

Lewis A, Bridges C, Moorshead D, Chen T, Du W, Zorman B Stem Cells. 2022; 40(8):736-750.

PMID: 35535819 PMC: 9406610. DOI: 10.1093/stmcls/sxac033.

RNAi-Mediated Screen of Primary AML Cells Nominates MDM4 as a Therapeutic Target in NK-AML with Mutations.

Sidorova O, Sayed S, Paszkowski-Rogacz M, Seifert M, Camgoz A, Roeder I Cells. 2022; 11(5).

PMID: 35269477 PMC: 8909053. DOI: 10.3390/cells11050854.

References

Cheung A, Wan T, Leung J, Chan L, Huang H, Kwong Y . Aldehyde dehydrogenase activity in leukemic blasts defines a subgroup of acute myeloid leukemia with adverse prognosis and superior NOD/SCID engrafting potential. Leukemia. 2007; 21(7):1423-30. DOI: 10.1038/sj.leu.2404721. View

Goodell M, Rosenzweig M, Kim H, Marks D, Demaria M, Paradis G . Dye efflux studies suggest that hematopoietic stem cells expressing low or undetectable levels of CD34 antigen exist in multiple species. Nat Med. 1997; 3(12):1337-45. DOI: 10.1038/nm1297-1337. View

Hauswirth A, Florian S, Printz D, Sotlar K, Krauth M, Fritsch G . Expression of the target receptor CD33 in CD34+/CD38-/CD123+ AML stem cells. Eur J Clin Invest. 2006; 37(1):73-82. DOI: 10.1111/j.1365-2362.2007.01746.x. View

Krivtsov A, Twomey D, Feng Z, Stubbs M, Wang Y, Faber J . Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature. 2006; 442(7104):818-22. DOI: 10.1038/nature04980. View

Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Minden M . A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature. 1994; 367(6464):645-8. DOI: 10.1038/367645a0. View

Jordan C, Upchurch D, Szilvassy S, Guzman M, Howard D, PETTIGREW A . The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia. 2000; 14(10):1777-84. DOI: 10.1038/sj.leu.2401903. View

Larson R, Boogaerts M, Estey E, Karanes C, Stadtmauer E, Sievers E . Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin). Leukemia. 2002; 16(9):1627-36. DOI: 10.1038/sj.leu.2402677. View

Owens B, Hawley R . HOX and non-HOX homeobox genes in leukemic hematopoiesis. Stem Cells. 2002; 20(5):364-79. DOI: 10.1634/stemcells.20-5-364. View

van Rhenen A, Moshaver B, Kelder A, Feller N, Nieuwint A, Zweegman S . Aberrant marker expression patterns on the CD34+CD38- stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission. Leukemia. 2007; 21(8):1700-7. DOI: 10.1038/sj.leu.2404754. View

10.

Huntly B, Shigematsu H, Deguchi K, Lee B, Mizuno S, Duclos N . MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. Cancer Cell. 2004; 6(6):587-96. DOI: 10.1016/j.ccr.2004.10.015. View

11.

Guzman M, Upchurch D, Grimes B, Howard D, Rizzieri D, Luger S . Expression of tumor-suppressor genes interferon regulatory factor 1 and death-associated protein kinase in primitive acute myelogenous leukemia cells. Blood. 2001; 97(7):2177-9. DOI: 10.1182/blood.v97.7.2177. View

12.

Jin L, Hope K, Zhai Q, Smadja-Joffe F, Dick J . Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med. 2006; 12(10):1167-74. DOI: 10.1038/nm1483. View

13.

Guzman M, Rossi R, Neelakantan S, Li X, Corbett C, Hassane D . An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. Blood. 2007; 110(13):4427-35. PMC: 2234793. DOI: 10.1182/blood-2007-05-090621. View

14.

van Rhenen A, van Dongen G, Kelder A, Rombouts E, Feller N, Moshaver B . The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells. Blood. 2007; 110(7):2659-66. DOI: 10.1182/blood-2007-03-083048. View

15.

Mayo M, Baldwin A . The transcription factor NF-kappaB: control of oncogenesis and cancer therapy resistance. Biochim Biophys Acta. 2000; 1470(2):M55-62. DOI: 10.1016/s0304-419x(00)00002-0. View

16.

Buchner T, Krug U, Berdel W, Heinecke A, Sauerland M, Wormann B . Maintenance for acute myeloid leukemia revisited. Curr Treat Options Oncol. 2007; 8(4):296-304. DOI: 10.1007/s11864-007-0041-1. View

17.

Spoo A, Lubbert M, Wierda W, Burger J . CXCR4 is a prognostic marker in acute myelogenous leukemia. Blood. 2006; 109(2):786-91. DOI: 10.1182/blood-2006-05-024844. View

18.

Xu Q, Simpson S, Scialla T, Bagg A, Carroll M . Survival of acute myeloid leukemia cells requires PI3 kinase activation. Blood. 2003; 102(3):972-80. DOI: 10.1182/blood-2002-11-3429. View

19.

Simon M, Grandage V, Linch D, Khwaja A . Constitutive activation of the Wnt/beta-catenin signalling pathway in acute myeloid leukaemia. Oncogene. 2005; 24(14):2410-20. DOI: 10.1038/sj.onc.1208431. View

20.

Hess D, Meyerrose T, Wirthlin L, Craft T, Herrbrich P, Creer M . Functional characterization of highly purified human hematopoietic repopulating cells isolated according to aldehyde dehydrogenase activity. Blood. 2004; 104(6):1648-55. DOI: 10.1182/blood-2004-02-0448. View